SAN DIEGO, CALIFORNIA, JULY 2025 — iCFO Capital Global is proud to announce its strategic partnership with SOHM Inc. SOHM, Inc. is a U.S.-based pharmaceutical and biotech company is headquartered in Chino Hills, California. Since its founding in 2005, the company has focused on the development, manufacturing, and global distribution of generic and branded generic drugs, over-the-counter (OTC) healthcare products, nutraceuticals, and Cosmeceuticals. With a strong manufacturing presence in Southern California, SOHM operates FDA-, EPA-, and cGMP-certified facilities that support a wide range of product types and formulations.
The company’s motto, “Innovate, Integrate, Inspire,” reflects its commitment to innovation in healthcare, seamless integration of technologies, and inspiration through responsible and sustainable business practices. In addition to traditional pharmaceutical manufacturing, SOHM has entered the biotech space with a groundbreaking gene-editing platform called ABBIE. This proprietary integrase tool has patents granted in China and pending in several major markets, including the U.S., EU, Japan, and South Korea. ABBIE is designed to improve precision and safety in gene therapy applications, particularly in areas like cancer and CAR-T cell therapy. SOHM recently shifted ABBIE’s commercialization strategy to a licensing model aimed at biotech companies, positioning the technology as a high-value asset in the growing gene-editing industry.
SOHM also offers private label and contract manufacturing services, providing custom formulation, scalable production, and rapid turnaround solutions for clients across the U.S. and international markets. Their product lines include popular items such as Levetiracetam (a generic anti-epileptic medication), topical antifungal treatments, nutritional supplements, and health-focused consumer goods like hand sanitizers and vitamin gummies. SOHM continues to gain recognition for its growth and innovation. In 2012, the company was honored as the “Fastest Growing Generics Prescription Drug Manufacturer” at the NIMA conference in India. More recently, they acquired an FDA-licensed facility in Santa Ana, California, to expand their production capacity and serve the growing demand for OTC and wellness products.
With its combined focus on affordable healthcare, cutting-edge biotech, and global distribution, SOHM is emerging as a dynamic player in both the pharmaceutical and gene therapy markets.
David Aguilar, PhD — Chief Operating Officer. Dr. Aguilar brings 22 years of CMC, quality-assurance and genome-editing expertise to SOHM. Formerly a Board Advisor, he now oversees global operations and ABBIE development, leveraging extensive IND experience in allogeneic cell-therapy manufacturing.
Leonardo Mirandola, PhD — Scientific Development Advisor & Execution Lead. Dr. Mirandola is a biopharma scientist with more than a decade of translational oncology and cell therapy experience. He leads SOHM’s ABBIE-based cell therapy initiatives and has guided multiple IND-track programs.
For more information about the company, please visit: https://sohm.com/
iCFO Capital Global, Inc. provides a platform for Entrepreneurs to connect with our Private Investors who make direct debt and equity investments for early-stage and expanding growth businesses. To learn more about how your business can secure the funding it needs, visit: https://www.icfocapital.com/
Media disclaimer: “Information herein is for general information purposes only. No offer or solicitation of securities is made or implied.”
This communication is intended for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any securities offering will be made only pursuant to an exemption from registration under the Securities Act of 1933, including Regulation D, and only to accredited investors. iCFO Capital Global is not a registered broker-dealer and does not provide transaction-based compensation or investment advisory services.